Pacira Biosciences Inc PCRX:NASDAQ

Last Price$60.77NASDAQ Previous Close - Last Trade as of 3:59PM ET 9/18/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$59.00 (4)
Ask (Size)$65.93 (32)
Day Low / HighN/A - N/A
Volume610.1 K
 

View Pharmaceuticals: Other IndustryPeer Comparison as of 09/18/2020

 

Pacira Biosciences Inc ( NASDAQ )

Price: $60.77
Change: +0.88 (1.47%)
Volume: 610.1 K
3:59PM ET 9/18/2020
 
 

Axsome Therapeutics Inc ( NASDAQ )

Price: $81.65
Change: +2.57 (3.25%)
Volume: 674.0 K
4:00PM ET 9/18/2020
 
 

Revance Therapeutics Inc ( NASDAQ )

Price: $31.95
Change: -0.16 (0.50%)
Volume: 2.1 M
4:00PM ET 9/18/2020
 
 

Corcept Therapeutics Inc ( NASDAQ )

Price: $17.99
Change: +0.77 (4.50%)
Volume: 2.0 M
3:59PM ET 9/18/2020
 
 

SAGE Therapeutics Inc ( NASDAQ )

Price: $62.45
Change: +2.35 (3.91%)
Volume: 1.6 M
4:00PM ET 9/18/2020
 

Read more news Recent News

Pacira BioSciences Receives Positive European Medicines Agency Opinion for Exparel to Treat Postsurgical Pain
9:45AM ET 9/18/2020 MT Newswires

Pacira BioSciences (PCRX) said Friday that the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Exparel...

Pacira BioSciences, IPG Sign Collaboration Deal to Reduce Postsurgical Opioid Prescribing, Surgical Procedure Costs
12:13PM ET 9/15/2020 MT Newswires

Pacira BioSciences (PCRX) and surgical cost management company IPG have signed a a collaboration deal intended to reduce postsurgical opioid prescribing...

Insider Trends: Insider Prolongs 90-Day Selling Trend at Pacira Biosciences
8:06PM ET 9/11/2020 MT Newswires

On Sep 09, 2020, Director, Dr Andreas Wicki, executed a sale of 2,216 shares in Pacira Biosciences (PCRX) for $137,436. Dr Wicki, subsequent to the...

--Analyst Actions: Needham Adjusts Price Target on Pacira BioSciences to $68 From $64, Maintains Buy
12:07PM ET 9/09/2020 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionPacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ. View company web site for more details
Address5 Sylvan Way
Parsippany, New Jersey 07054
Phone+1.973.254.3560
Number of Employees518
Recent SEC Filing09/17/20204
Chairman, Chief Executive & Operating OfficerDavid M. Stack
Chief Financial OfficerCharles A. Reinhart
Vice President-Research & DevelopmentVladimir Kharitonov
Chief Technology OfficerCharles Anthony Laranjeira

Company Highlights

Price Open$60.91
Previous Close$59.89
52 Week Range$27.46 - 64.44
Market Capitalization$2.6 B
Shares Outstanding42.7 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement11/05/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share$0.09
Beta vs. S&P 500N/A
Revenue$337.3 M
Net Profit Margin-2.47%
Return on Equity-2.76%

Analyst Ratings as of 08/30/2020

Buy
9
Overweight
0
Hold
4
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset